BeyondSpring’s Pivotal NSCLC Trial For Plinabulin Designed To Avoid Bavencio’s JAVELIN 200 Failure
Lessons learned about blinding and stratification from Pfizer and Merck KGaA’s earlier Phase III disappointment shaped the design of BeyondSpring's ongoing Phase III trial of plinabulin in second- and third-line non-small cell lung cancer.
You may also be interested in...
BeyondSpring’s lead clinical asset, plinabulin, is currently in late-stage global registrational studies for the prevention of chemotherapy-induced neutropenia and treatment of lung cancer, with read-outs expected soon. CEO Lan Huang discussed coming catalysts and their potential with Scrip.
The firms still hope to produce positive data in first-line non-small cell lung cancer in 2019, but Bavencio is falling well behind its checkpoint inhibitor competition.
Keeping Track: Rebyota, Rezlidhia Rev Up US FDA Approvals; New Sponsors Sought For Poziotinib, Brexafemme
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.